Public health genomics and personalized healthcare  by Brand, A.
Parallel Session Abstracts
2013 e113
These include siRNA and microRNA used to degrade mRNA tran-
scripts and suppress protein translation, and antisense oligonucleo-
tides used to manipulate splicing.
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Summary: The use of vitamin K antagonists (VKA) is challenging 
because of their narrow therapeutic index and a large interindividual 
variability. Pauci data were available regarding the relative contribu-
tion of pharmacogenetic and nongenetic factors to VKA response 
in specific populations (elderly, children, resistant patients). In 2 
cohorts of elderly patients receiving warfarin (n = 300) or fluin-
dione (n = 156), genetic factors were the main determinants of the 
maintenance dose, explaining ~20% of the variability versus ~10% 
for nongenetic factors. The variables significantly associated with the 
maintenance dose were VKORC1/CYP2C9/CYP4F2/EPHX1 and age 
for warfarin, and VKORC1/ABCB/CYP4F2, weight, and amiodar-
one intake for fluindione by multivariate analysis. During warfarin 
initiation, VKORC1 genotype had a strong predictive value for war-
farin sensitivity. When building prediction models of the warfarin 
dose, VKORC1/CYP2C9 were the best predictors before initiation, 
whereas their contribution was negligible once INR value was avail-
able after starting warfarin using a standardized regimen.
In the children cohort (n = 120), height and VKORC1/CYP2C9 
were the main determinants of warfarin dose requirement, explaining 
70% of the variability accounting for 48% and 20%, respectively.
Among the 100 patients resistant referred to us for analysis, only 
30 patients were carriers of VKORC1 mutations for which in vitro 
functional characterization was performed. Our results suggest the 
involvement of other genetic factors in VKA resistance.
Pharmacogenetics will help the development of personalized med-
icine to improve safety and efficacy during VKA treatment. Whether 
genetic testing improves long-term anticoagulation control in patients 
receiving VKA and prone to instability remains to be determined.
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Summary: Rapid scientific advances and tools in genomics such 
as in the light of epigenomics, microbiomics, and systems biology 
supported by new ICT solutions not only contribute to the under-
standing of disease mechanisms but also provide the option of new 
promising applications in human health management during the 
whole life-course. What was a little time ago a vision for a new era 
of public health, in which advances from the -omic sciences would 
be integrated into strategies aiming at benefiting population health, 
is now responding to the very pressing need for the development of 
effective personalized health care, going even beyond personalized 
medicine based on a systems medicine approach. Although the utility 
of most genetic tests and biomarkers is still not evidence based, the 
real take-home message stops here and is a different one. In the per-
sonalized medicine setting, the traditional assessment and evaluation 
tools just do not work anymore. Thus, we clearly face the need for 
a new paradigm moving from population health to personal health. 
The paradigm shift depends on the willingness to restructure poli-
cies, and there is a clear urgency to prepare health care systems and 
policy makers in time.
So far, all stakeholders, including policy makers and the pri-
vate sector, are struggling to translate the emerging knowledge 
into public health. Public Health Genomics (PHG) is the area of 
public health ensuring that scientific advances in genomics (“from 
cell...”) triggered by innovative technologies are timely, effectively, 
and responsibly translated into health policies and practice for the 
benefit of population health (“...to society”). The implementation of 
PHG requires increased concerted activities. The Institute for Public 
Health Genomics (IPHG) at Maastricht University aims to fulfill 
this task in all European Member States by hosting the European 
Centre for Public Health Genomics (ECPHG) and coordinating the 
Public Health Genomics European Network (PHGEN). Furthermore, 
it closely collaborates with the European Science Foundation (ESF 
Forward Look on Personalised Medicine), the European Alliance 
for Personalised Medicine (EAPM), and the European Flagship Pilot 
ITFoM on the future of medicine, being one of the most ambitious 
worldwide, large-scale, science-driven, research initiatives that aim 
to achieve the visionary goal of the “virtual human.”
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Summary: One of the core objectives of medical curricula is to provide 
graduates with a sufficient level of therapeutic knowledge and skills. 
Over the last decade, a lot has changed when it comes to teaching 
medical students how to prescribe rationally. In the Netherlands, most 
medical curricula shifted from a so-called problem-based learning to 
a context-learning pharmacotherapy program. However, there is still 
no systematic approach available for assessing students’ therapeu-
tic knowledge and skills during such a context-learning curriculum. 
Research on this topic consists almost exclusively of descriptive and 
evaluative studies on different assessment methods. These studies show 
that the often-used single-shot assessments have their shortcomings 
and poorly meet the recent developments in medical education (con-
text-learning). What is needed is a systematic approach to assessment.
In this session, David Brinkman proposes a new systematic model 
(TRACK) for assessing students’ therapeutic knowledge, skills/com-
petencies, and attitude during a context-learning curriculum. This 
longitudinal model is based on a set of assessment principles that are 
interpreted from empirical evidence. He discusses a number of chal-
lenges and opportunities around the proposed model and presents 
preliminary findings of this new project. One of its prime virtues is 
that it enables therapeutic assessment toward an assessment design 
that is underpinned by empirically grounded theory and, moreover, 
carefully follows students until they are prescribers.
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